Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store. Buying stocks after they have lost significant market ...

Novavax NVAX is expected to report fourth-quarter and full-year 2024 earnings later this month. In the last reported quarter, the company’s earnings beat estimates by 12.64%. The Zacks Consensus ...

Novavax (NVAX) ended the recent trading session at $7.92, demonstrating a -1.25% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily loss of 0.43%.

Novavax stock (NVAX) skyrocketed Friday ... While Novavax's vaccine did finally reach the market in mid-2022, targeting the booster market, it continued to struggle with $1.7 billion in ...

Short interest in Novavax Inc (NASDAQ:NVAX) increased during the last reporting period, rising from 35.45M to 39.23M. This put 30.38% of the company's publicly available shares short. Short ...

GAITHERSBURG, Md. (AP) — GAITHERSBURG, Md. (AP) — Novavax Inc. (NVAX) on Thursday reported a loss of $81 million in its fourth quarter. On a per-share basis, the Gaithersburg, Maryland-based ...